Kosei Tajima

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Takashi Seto, Terufumi Kato, Makoto Nishio et al. · The Lancet Oncology · 2014 · 749 citations

Medicine, Oncology, Pharmacology +14

Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results

Terufumi Kato, Takashi Seto, Makoto Nishio et al. · Drug Safety · 2017 · 59 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer

Toru Sugiyama, Mika Mizuno, Yoichi Aoki et al. · Japanese Journal of Clinical Oncology · 2016 · 29 citations · Full text

Medicine, Oncology, Pharmacology +14

Erlotinib for Japanese Patients with Activating <i>EGFR</i> Mutation-Positive Non-Small-Cell Lung Cancer: Combined Analyses from Two Phase II Studies

Shinji Atagi, Kōichi Goto, Takashi Seto et al. · Future Oncology · 2016 · 15 citations · Full text

Medicine, Oncology, Pharmacology +13

Accuracy of algorithms to identify patients with a diagnosis of major cancers and cancer-related adverse events in an administrative database: a validation study in an acute care hospital in Japan

Takashi Fujiwara, Takashi Kanemitsu, Kosei Tajima et al. · BMJ Open · 2022 · 15 citations · Full text

Health Professions, Health Informatics, Oncology +15